BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sullivan C. The preferential homing of mesenchymal stromal cells to sites of inflammation. In: Atkinson K, editor. The Biology and Therapeutic Application of Mesenchymal Cells. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 286-313. [DOI: 10.1002/9781118907474.ch22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Lupu‐haber Y, Bronshtein T, Shalom‐luxenburg H, D'atri D, Oieni J, Kaneti L, Shagan A, Hamias S, Amram L, Kaneti G, Cohen Anavy N, Machluf M. Pretreating Mesenchymal Stem Cells with Cancer Conditioned‐Media or Proinflammatory Cytokines Changes the Tumor and Immune Targeting by Nanoghosts Derived from these Cells. Adv Healthcare Mater 2019;8:1801589. [DOI: 10.1002/adhm.201801589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Qindeel M, Sabir F, Sargazi S, Mohammadzadeh V, Mulla SI. New insights into the application of nanoghosts as theranostic tools with an emphasis on cardiovascular diseases. J Nanopart Res 2021;23. [DOI: 10.1007/s11051-021-05370-7] [Reference Citation Analysis]